From Name:
From Email:
To Name:
To Email:

Optional Message:

Novel Cell Therapy Cuts Clinical Events in Advanced HF

from Medscape

Ixmyelocel-T met its primary end point in patients with end-stage heart failure due to ischemic dilated cardiomyopathy in the ixCELL-DCM trial, its maker, Vericel, announced. Transendocardial catheter-based injections of ixmyelocel-T reduced the number of deaths, cardiovascular hospitalizations or unplanned outpatient and emergency-department visits to treat acute decompensated heart failure compared with placebo in the 12 months following treatment. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063